Revolution stalled.
Drug discovery is at a near standstill for treating psychiatric disorders such as schizophrenia, bipolar disorder, depression, and common forms of autism. Despite high prevalence and unmet medical need, major pharmaceutical companies are deemphasizing or exiting psychiatry, thus removing significant capacity from efforts to discover new medicines. In this Commentary, I develop a view of what has gone wrong scientifically and ask what can be done to address this parlous situation.
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. seh@harvard.edu
Steven E
SE
Hyman
D001321:Autistic Disorder / Q000188:drug therapy / Q000378:metabolism; D001714:Bipolar Disorder / Q000188:drug therapy / Q000378:metabolism; D055808:Drug Discovery; D006801:Humans; D004364:Pharmaceutical Preparations; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism
D004364:Pharmaceutical Preparations